Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 10, 2000, Pages 2623-2629

  Jenks, P J ^a   Ferrero, R L ^a   Tankovic, J ^a   Thiberge, J M ^a   Labigne, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; METRONIDAZOLE; NITROFURANTOIN; NITROREDUCTASE; OMEPRAZOLE;

ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; ERADICATION THERAPY; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTI-INFECTIVE AGENTS, URINARY; ANTITRICHOMONAL AGENTS; BACTERIAL PROTEINS; CLONING, MOLECULAR; DNA PRIMERS; DRUG RESISTANCE, MICROBIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MEMBRANE PROTEINS; METRONIDAZOLE; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; NITROFURANTOIN; OXIDATION-REDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0033797824     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.10.2623-2629.2000     Document Type: Article

References (57)

1. Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
2. The reduction of furacin by cell-free extracts of furacin-resistant and parent-susceptible strains of Escherichia coli
3. Helicobacter pylori: Microbiology of a 'slow' bacterial infection
4. Monotherapy or polychemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease
5. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance
6. Analysis of gene control signals by DNA fusions and cloning in E. coli
7. In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori
8. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer
9. A therapeutic trial in Giardia muris infection in the mouse with metronidazole, tinidazole, secnidazole and furazolidone
10. Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer
11. Helicobacter pylori
12. Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report
13. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori
14. Immune responses of specific-pathogen-free mice to chronic Helicobacter pylori (strain SS1) infection
15. The therapeutic activity of some nitrofurans in experimental filariasis and trypanosomiasis
16. Susceptibility of clinical isolates of Campylobacter pylori to 24 antimicrobial and anti-ulcer agents
17. Getting to the route of Helicobacter pylori treatment
18. Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase
19. Antimicrobial treatment of Helicobacter pylori infection
20. Choosing the best anti-Helicobacter pylori therapy: Effect of antimicrobial resistance
21. Simple noninvasive method to test efficacy of drugs in the eradication of Helicobacter pylori infection: The example of combined bismuth subsalicylate and nitrofurantoin
22. In vitro selection of resistant Helicobacter pylori
23. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection
24. Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis
25. Phenotypic changes of Helicobacter pylori components during experimental infection in mice
26. The role of the rdxA gene in the evolution of metronidazole resistance in Helicobacter pylori
27. Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice
28. Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: Identification from sequential and multiple biopsy specimens
29. Antimicrobial therapies for Helicobacter pylori infection in gnotobiotic piglets
30. Shuttle cloning and nucleotide sequence of Helicobacter pylori genes responsible for urease activity
31. Gene disruption and replacement as a feasible approach for mutagenesis of Campylobacter jejuni
32. A standardized mouse model of Helicobacter pylori infection: Introducing the Sydney strain
33. Furazolidone-containing short-term therapies are effective in the treatment of Helicobacter pylori infection
34. Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates from Spain
35. Genetics of nitrofurazone resistance in Escherichia coli
36. Nitrofurantoin: Mechanism of action and implications for resistance development in common uropathogens
37. Clinical relevance of resistant strains of Helicobacter pylori: A review of current data
38. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole
39. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori
40. Susceptibility patterns of Campylobacter pyloridis
41. Helicobacter pylori infection and the risk of gastric cancer
42. Helicobacter pylori infection and gastric lymphoma
43. Role of metronidazole in therapy of Helicobacter pylori infections
44. Vitamin C concentration in gastric juice before and after anti-Helicobacter pylori treatment
45. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection
46. Comparative in vitro activities of six new fluoroquinolones and other oral antimicrobial agents against Campylobacter pylori
47. Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori
48. The complete genome sequence of the gastric pathogen Helicobacter pylori
49. In vivo transfer of genetic information between gram-positive and gram-negative bacteria
50. Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication
51. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands
52. Transformation of Helicobacter pylori by chromosomal metronidazole resistance and by a plasmid with a selectable chloramphenicol resistance marker
53. Unidentified curved bacilli on gastric epithelium in chronic active gastritis
54. Oxygen-insensitive nitroreductases: Analysis of the roles of nfsA and nfsB in development of resistance to 5-nitrofuran derivatives in Escherichia coli
55. Guidelines for clinical trials in Helicobacter pylori infection
56. High cure rate of Helicobacter pylori infection using tripotassium bismuthate, furazolidone and clarithromycin triple therapy for 1 week